BETMAT touts recombinant rFC endotoxin testing for parenteral drug QC

BETMAT Biotechnology LLC is pitching a recombinant Factor C endotoxin test as a cleaner alternative to horseshoe crab-based LAL assays for parenteral drug quality control. The company says the animal-free method can reduce beta-glucan interference, improve consistency and support regulatory compliance for biologics manufacturing.

Why it matters: - Parenteral drugs such as injectables, vaccines and monoclonal antibodies can enter the bloodstream directly, so endotoxin control is critical to patient safety and regulatory compliance. - BETMAT Biotechnology LLC is positioning recombinant Factor C testing as an animal-free alternative to traditional LAL assays, which depend on horseshoe crab blood. - A shift to recombinant testing could reduce reliance on a constrained marine resource and improve supply-chain stability for pharmaceutical quality control.

What happened: - BETMAT Biotechnology LLC said its BETMAT-branded Recombinant Factor C, or rFC, fluorometric assay is designed for endotoxin testing in modern biopharmaceutical manufacturing. - The company released details on the platform June 9, 2026, from Dover, Delaware. - The assay is intended for use in quality control workflows for parenteral drug products and other regulated biologics.

The details: - The BETMAT rFC assay uses recombinant Factor C expressed in vitro from the endotoxin-recognition domain of horseshoe crab biology. - When endotoxin is present, lipopolysaccharides bind to recombinant Factor C and trigger cleavage of a fluorogenic substrate. - The reaction releases 7-amino-4-methylcoumarin, or AMC, which is measured as fluorescence in a microplate reader. - BETMAT says the assay has a lower limit of detection as low as 0.005 EU/mL. - The company says the linear dynamic range runs from 0.005 to 5 EU/mL. - BETMAT says the reagents are produced under controlled manufacturing conditions to reduce batch-to-batch variability. - The workflow uses a microplate format and is described as compatible with standard laboratory automation and robotic liquid handling. - A typical assay cycle takes 1 to 2 hours. - BETMAT says the data can be integrated into laboratory information management systems to support traceability and electronic records compliance.

Between the lines: - Traditional LAL assays can react to (1→3)-β-D-glucans, which can create false positives or require extra confirmation testing. - BETMAT says its recombinant system removes Factor G and other glucan-responsive components, so the assay is not affected by (1→3)-β-D-glucans. - That specificity could matter for complex biologics, where matrix effects can mask endotoxin or interfere with detection chemistry. - BETMAT is also framing the product as a sustainability play, since recombinant reagents avoid harvesting and bleeding horseshoe crabs. - The company is tying the assay to international regulatory frameworks, including USP Chapter <85> and European Pharmacopoeia Chapter 2.6.14.

What's next: - BETMAT says pharmaceutical manufacturers can use the rFC platform within existing regulatory frameworks and may face a reduced validation burden versus other novel methods. - The company is offering the assay alongside other endotoxin and pyrogen-control products, including kinetic chromogenic and turbidimetric LAL reagents, Monocyte Activation Test systems and (1,3)-beta-D-glucan diagnostic kits. - BETMAT directs customers to the company's website for more information on recombinant testing kits and endotoxin detection products.

The bottom line: - BETMAT is betting that recombinant endotoxin testing can deliver cleaner data, fewer animal-derived inputs and a more stable supply chain for pharma QC.